Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene

1985 • 1,804 citations

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

1992 • 1,200 citations

The neu oncogene encodes an epidermal growth factor receptor-related protein

1986 • 1,131 citations

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

1990 • 640 citations

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

1994 • 467 citations

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

2001 • 436 citations

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

1999 • 339 citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1996 • 308 citations

Epitope spreading

1996 • 302 citations

Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing.

1992 • 265 citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1996 • 256 citations

Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants.

1992 • 219 citations

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

2000 • 214 citations

Induction of anti-self-immunity to cure cancer

1995 • 207 citations

Improving Vaccine Performance with Adjuvants

2000 • 193 citations

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1996 • 185 citations

HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer

1997 • 173 citations

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

2000 • 161 citations

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.

2000 • 113 citations

In vivopriming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen

1998 • 108 citations

Mapping the major human T helper epitopes of tetanus toxin. The emerging picture.

1993 • 104 citations

MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope

1999 • 86 citations

HER-2/neu Oncogenic Protein: Issues in Vaccine Development

1998 • 80 citations

Driver Clones and Determinant Spreading

2000 • 79 citations

105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses

2000 • 46 citations

Antigen Processing Differences Among APC

1997 • 36 citations

Antigen-specific recall urticaria to a peptide-based vaccine☆☆☆★★★

1999 • 16 citations

Residual public repertoires to self

2000 • 12 citations

Characterization of tumor vaccines during product development

2000 • 9 citations